CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells

Summary: The apoptosis inducing receptor CD95/Fas has multiple tumorigenic activities. In different genetically engineered mouse models tumor-expressed CD95 was shown to be critical for cell growth. Using a combination of immune-deficient and immune-competent mouse models, we now establish that loss...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abdul S. Qadir, Jean Philippe Guégan, Christophe Ginestier, Assia Chaibi, Alban Bessede, Emmanuelle Charafe-Jauffret, Manon Macario, Vincent Lavoué, Thibault de la Motte Rouge, Calvin Law, Jacob Vilker, Hongbin Wang, Emily Stroup, Matthew J. Schipma, Bryan Bridgeman, Andrea E. Murmann, Zhe Ji, Patrick Legembre, Marcus E. Peter
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Immunology Cell biology Cancer Science Q
Acceso en línea:	https://doaj.org/article/01c1b9341da244a5b4a9946be1c614bf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:01c1b9341da244a5b4a9946be1c614bf
record_format	dspace
spelling	oai:doaj.org-article:01c1b9341da244a5b4a9946be1c614bf2021-11-20T05:10:19ZCD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells2589-004210.1016/j.isci.2021.103348https://doaj.org/article/01c1b9341da244a5b4a9946be1c614bf2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2589004221013171https://doaj.org/toc/2589-0042Summary: The apoptosis inducing receptor CD95/Fas has multiple tumorigenic activities. In different genetically engineered mouse models tumor-expressed CD95 was shown to be critical for cell growth. Using a combination of immune-deficient and immune-competent mouse models, we now establish that loss of CD95 in metastatic triple negative breast cancer (TNBC) cells prevents tumor growth by modulating the immune landscape. CD95-deficient, but not wild-type, tumors barely grow in an immune-competent environment and show an increase in immune infiltrates into the tumor. This growth reduction is caused by infiltrating NK cells and does not involve T cells or macrophages. In contrast, in immune compromised mice CD95 k.o. cells are not growth inhibited, but they fail to form metastases. In summary, we demonstrate that in addition to its tumor and metastasis promoting activities, CD95 expression by tumor cells can exert immune suppressive activities on NK cells, providing a new target for immune therapy.Abdul S. QadirJean Philippe GuéganChristophe GinestierAssia ChaibiAlban BessedeEmmanuelle Charafe-JauffretManon MacarioVincent LavouéThibault de la Motte RougeCalvin LawJacob VilkerHongbin WangEmily StroupMatthew J. SchipmaBryan BridgemanAndrea E. MurmannZhe JiPatrick LegembreMarcus E. PeterElsevierarticleImmunologyCell biologyCancerScienceQENiScience, Vol 24, Iss 11, Pp 103348- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunology Cell biology Cancer Science Q
spellingShingle	Immunology Cell biology Cancer Science Q Abdul S. Qadir Jean Philippe Guégan Christophe Ginestier Assia Chaibi Alban Bessede Emmanuelle Charafe-Jauffret Manon Macario Vincent Lavoué Thibault de la Motte Rouge Calvin Law Jacob Vilker Hongbin Wang Emily Stroup Matthew J. Schipma Bryan Bridgeman Andrea E. Murmann Zhe Ji Patrick Legembre Marcus E. Peter CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells
description	Summary: The apoptosis inducing receptor CD95/Fas has multiple tumorigenic activities. In different genetically engineered mouse models tumor-expressed CD95 was shown to be critical for cell growth. Using a combination of immune-deficient and immune-competent mouse models, we now establish that loss of CD95 in metastatic triple negative breast cancer (TNBC) cells prevents tumor growth by modulating the immune landscape. CD95-deficient, but not wild-type, tumors barely grow in an immune-competent environment and show an increase in immune infiltrates into the tumor. This growth reduction is caused by infiltrating NK cells and does not involve T cells or macrophages. In contrast, in immune compromised mice CD95 k.o. cells are not growth inhibited, but they fail to form metastases. In summary, we demonstrate that in addition to its tumor and metastasis promoting activities, CD95 expression by tumor cells can exert immune suppressive activities on NK cells, providing a new target for immune therapy.
format	article
author	Abdul S. Qadir Jean Philippe Guégan Christophe Ginestier Assia Chaibi Alban Bessede Emmanuelle Charafe-Jauffret Manon Macario Vincent Lavoué Thibault de la Motte Rouge Calvin Law Jacob Vilker Hongbin Wang Emily Stroup Matthew J. Schipma Bryan Bridgeman Andrea E. Murmann Zhe Ji Patrick Legembre Marcus E. Peter
author_facet	Abdul S. Qadir Jean Philippe Guégan Christophe Ginestier Assia Chaibi Alban Bessede Emmanuelle Charafe-Jauffret Manon Macario Vincent Lavoué Thibault de la Motte Rouge Calvin Law Jacob Vilker Hongbin Wang Emily Stroup Matthew J. Schipma Bryan Bridgeman Andrea E. Murmann Zhe Ji Patrick Legembre Marcus E. Peter
author_sort	Abdul S. Qadir
title	CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells
title_short	CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells
title_full	CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells
title_fullStr	CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells
title_full_unstemmed	CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells
title_sort	cd95/fas protects triple negative breast cancer from anti-tumor activity of nk cells
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/01c1b9341da244a5b4a9946be1c614bf
work_keys_str_mv	AT abdulsqadir cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT jeanphilippeguegan cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT christopheginestier cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT assiachaibi cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT albanbessede cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT emmanuellecharafejauffret cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT manonmacario cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT vincentlavoue cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT thibaultdelamotterouge cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT calvinlaw cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT jacobvilker cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT hongbinwang cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT emilystroup cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT matthewjschipma cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT bryanbridgeman cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT andreaemurmann cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT zheji cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT patricklegembre cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells AT marcusepeter cd95fasprotectstriplenegativebreastcancerfromantitumoractivityofnkcells
_version_	1718419520145588224

CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells

Ejemplares similares